Researchers at Memorial Sloan Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy.

Adverse Effects of Robotic-Assisted Laparoscopic Versus Open Retropubic Radical Prostatectomy Among a Nationwide Random Sample of Medicare-Age Men There is currently no imaging biomarker for ...

A first-in-human phase 1 study of proxalutamide (GT0918), a dual MOA androgen receptor blocker in patients with advanced CRPC. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I.

Figure 1. A 74-y-old man at initial staging with PSMA PET that demonstrates low uptake in primary tumor (A, arrowhead) and left pelvic side wall node (A, arrow). Bone scan was read as positive by 2 of ...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI ...

Use of computed tomography and bone scans in low-risk prostate cancer cases has been in decline, but doctors continue to order these imaging modalities despite professional guidelines that do not ...